published meta-analysis   sensitivity analysis   studies

potential COVID-19 treatments in COVID-19 severe or critically - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsCOALITION II Covid-19 Brazil (Furtado), 2020 1.08 [0.79; 1.47] HYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24] 0.97[0.73; 1.29]COALITION II Covid-19 Brazil (Furtado), 2020, HYDRA (Hernandez-Cardenas), 2021216%611moderatenot evaluable deathsdetailed resultsCao, 2020 0.71 [0.36; 1.40] CAP-China (Wang et al.), 2020 1.10 [0.49; 2.45] COALITION II Covid-19 Brazil (Furtado), 2020 1.08 [0.79; 1.47] Galan, 2021 0.94 [0.51; 1.73] HYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24] REMAP-CAP (lopinavir/ritonavir only), 2020 0.83 [0.65; 1.06] REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.58 [0.36; 0.93] 0.86[0.74; 1.00]Cao, 2020, CAP-China (Wang et al.), 2020, COALITION II Covid-19 Brazil (Furtado), 2020, Galan, 2021, HYDRA (Hernandez-Cardenas), 2021, REMAP-CAP (lopinavir/ritonavir only), 2020, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 202070%2,265moderatenot evaluable deaths (time to event analysis only)detailed resultsCOALITION II Covid-19 Brazil (Furtado), 2020 1.08 [0.79; 1.47] Galan, 2021 0.94 [0.51; 1.73] HYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24] REMAP-CAP (lopinavir/ritonavir only), 2020 0.83 [0.65; 1.06] REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.58 [0.36; 0.93] 0.85[0.71; 1.03]COALITION II Covid-19 Brazil (Furtado), 2020, Galan, 2021, HYDRA (Hernandez-Cardenas), 2021, REMAP-CAP (lopinavir/ritonavir only), 2020, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020521%1,830moderatenot evaluable clinical deteriorationdetailed resultsCAP-China (Wang et al.), 2020 0.95 [0.55; 1.64] 0.95[0.55; 1.64]CAP-China (Wang et al.), 202010%237NAnot evaluable clinical improvementdetailed resultsCao, 2020 1.31 [0.94; 1.83] CAP-China (Wang et al.), 2020 1.23 [0.87; 1.74] COALITION II Covid-19 Brazil (Furtado), 2020 0.74 [0.51; 1.07] REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.63 [0.37; 1.06] 0.96[0.68; 1.35]Cao, 2020, CAP-China (Wang et al.), 2020, COALITION II Covid-19 Brazil (Furtado), 2020, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020468%1,040moderatenot evaluable clinical improvement (14-day)detailed resultsCao, 2020 1.94 [1.09; 3.48] CAP-China (Wang et al.), 2020 1.21 [0.64; 2.28] COALITION II Covid-19 Brazil (Furtado), 2020 0.74 [0.51; 1.07] REMAP-CAP (lopinavir/ritonavir only), 2020 0.85 [0.64; 1.12] REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.63 [0.37; 1.06] 0.94[0.68; 1.30]Cao, 2020, CAP-China (Wang et al.), 2020, COALITION II Covid-19 Brazil (Furtado), 2020, REMAP-CAP (lopinavir/ritonavir only), 2020, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020562%1,883moderatenot evaluable clinical improvement (28-day)detailed resultsCao, 2020 1.59 [0.84; 3.03] CAP-China (Wang et al.), 2020 1.37 [0.79; 2.39] COALITION II Covid-19 Brazil (Furtado), 2020 0.70 [0.47; 1.04] 1.10[0.64; 1.90]Cao, 2020, CAP-China (Wang et al.), 2020, COALITION II Covid-19 Brazil (Furtado), 2020368%832moderatenot evaluable clinical improvement (7-day)detailed resultsCao, 2020 3.16 [0.62; 16.06] CAP-China (Wang et al.), 2020 0.99 [0.18; 5.51] COALITION II Covid-19 Brazil (Furtado), 2020 0.94 [0.63; 1.40] 1.01[0.68; 1.50]Cao, 2020, CAP-China (Wang et al.), 2020, COALITION II Covid-19 Brazil (Furtado), 202031%832moderatenot evaluable clinical improvement (time to event analysis only)detailed resultsCao, 2020 1.31 [0.94; 1.83] CAP-China (Wang et al.), 2020 1.23 [0.87; 1.74] HYDRA (Hernandez-Cardenas), 2021 1.05 [0.74; 1.48] 1.19[0.98; 1.45]Cao, 2020, CAP-China (Wang et al.), 2020, HYDRA (Hernandez-Cardenas), 202130%451moderatenot evaluable hospital dischargedetailed resultsHYDRA (Hernandez-Cardenas), 2021 1.01 [0.72; 1.42] REMAP-CAP (lopinavir/ritonavir only), 2020 0.83 [0.69; 1.00] REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.63 [0.43; 0.92] 0.82[0.66; 1.02]HYDRA (Hernandez-Cardenas), 2021, REMAP-CAP (lopinavir/ritonavir only), 2020, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020340%1,265moderatenot evaluable mechanical ventilationdetailed resultsGalan, 2021 0.14 [0.03; 0.71] 0.14[0.03; 0.71]Galan, 202110%168NAnot evaluable ICU admissiondetailed resultsGalan, 2021 1.42 [0.68; 2.99] 1.42[0.68; 2.99]Galan, 202110%168NAnot evaluable off oxygenationdetailed resultsHYDRA (Hernandez-Cardenas), 2021 0.98 [0.64; 1.51] 0.98[0.64; 1.51]HYDRA (Hernandez-Cardenas), 202110%214NAnot evaluable AE leading to drug discontinuationdetailed resultsCAP-China (Wang et al.), 2020 2.43 [0.79; 7.45] 2.43[0.79; 7.45]CAP-China (Wang et al.), 202010%233NAnot evaluable related SAE (TRSAE)detailed resultsCOALITION II Covid-19 Brazil (Furtado), 2020 1.24 [0.50; 3.11] 1.24[0.50; 3.11]COALITION II Covid-19 Brazil (Furtado), 202010%439NAnot evaluable serious adverse eventsdetailed resultsCao, 2020 0.52 [0.27; 1.01] CAP-China (Wang et al.), 2020 0.64 [0.33; 1.23] COALITION II Covid-19 Brazil (Furtado), 2020 1.20 [0.82; 1.77] REMAP-CAP (lopinavir/ritonavir only), 2020 1.57 [0.70; 3.49] REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.97 [0.22; 4.33] 0.90[0.59; 1.38]Cao, 2020, CAP-China (Wang et al.), 2020, COALITION II Covid-19 Brazil (Furtado), 2020, REMAP-CAP (lopinavir/ritonavir only), 2020, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020547%1,872moderatenot evaluable deep vein thrombosisdetailed resultsCAP-China (Wang et al.), 2020 0.50 [0.03; 8.10] 0.50[0.03; 8.10]CAP-China (Wang et al.), 202010%233NAnot evaluable elevated liver enzymesdetailed resultsCAP-China (Wang et al.), 2020 0.36 [0.13; 1.01] 0.36[0.13; 1.01]CAP-China (Wang et al.), 202010%233NAnot evaluable hyperbilirubinemiadetailed resultsCAP-China (Wang et al.), 2020 1.09 [0.42; 2.79] 1.09[0.42; 2.79]CAP-China (Wang et al.), 202010%233NAnot evaluable long QTdetailed resultsCOALITION II Covid-19 Brazil (Furtado), 2020 0.90 [0.56; 1.43] 0.90[0.56; 1.43]COALITION II Covid-19 Brazil (Furtado), 202010%439NAnot evaluable pulmonary embolismdetailed resultsCAP-China (Wang et al.), 2020 0.50 [0.03; 8.10] 0.50[0.03; 8.10]CAP-China (Wang et al.), 202010%233NAnot evaluable renal impairmentdetailed resultsCAP-China (Wang et al.), 2020 1.01 [0.03; 30.33] COALITION II Covid-19 Brazil (Furtado), 2020 1.44 [0.99; 2.11] 1.44[0.98; 2.10]CAP-China (Wang et al.), 2020, COALITION II Covid-19 Brazil (Furtado), 202020%672moderatenot evaluable0.05.01.0relative treatment effectwww.metaEvidence.org2024-05-10 13:08 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 91 - treatments: 290,547,608,830,831,829,901,680,595,828,681,1209,833,629,689,543,617,625,859,511,960,546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525,843,827,1047,1048,819,545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814,649,650,589,651,968,1245,610,751,747,695,548,970,594,565,879,1257,571,626,697,572,1234,586,573,540,592,930,949,838,698,934,735,929,948,946,945,587,655,1146,531,933,613,919,725,678,921,621,959,748,1348,1256,924,1243,925,658,699,612,552,590,891,605,892,722,618,609,551,834,763,922,935,620,1317,1265,824,766,857,1291,1088,1331,1330,1329,1344,1328,1327,979,822,762,805,950,757,761,806,758,826,755,821,1288,1287,1286,760,1284,802,765,1285,759,823,804,1264,764,858,835,1262,1290,1316,1341,1342,1343,825,803,1244,523,885,734,1439 - roots T: 290